Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L12 pseudogene 26 (RPL12P26) is a **processed pseudogene** in the human genome related to the functional RPL12 gene, which encodes a component of the cytoplasmic 60S ribosomal subunit. Pseudogenes like RPL12P26 do not produce functional proteins; instead, they are noncoding genomic elements derived from ancestral genes by duplication or retrotransposition. There is no evidence this locus encodes a functional protein or serves as a direct disease marker or therapeutic target in humans[5][6][8]. RPL12P26 is a processed pseudogene, not a receptor, enzyme, or functional therapeutic target. There are no drugs, known disease roles, or mechanisms of action associated with it. Entry is considered "incorrect" in the context of therapeutic targeting.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L12 pseudogene 26 (RPL12P26).